仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Benralizumab （MEDI-563） is an interleukin-5 receptor α （IL-5Rα）-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma